Insmed Incorporated (Nasdaq: INSM) — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. Insmed is a biopharmaceutical company whose only approved product is ARIKAYCE; its clinical-stage pipeline includes brensocatib and TPIP. Financial statements received an unqualified audit opinion, and the auditor also reported effective internal control over financial reporting.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 | Change / context |
|---|---|---|---|
| Net product revenue | $305.2 million | $245.4 million | Up $59.9 million, or 24.4%; ARIKAYCE sales grew across regions |
| Cost of product revenue, excluding intangible amortization | $65.6 million | $55.1 million | 21.5% of revenue versus 22.5% |
| Gross profit, before intangible amortization | $239.6 million | — | Calculated as revenue less stated cost of product revenue; approximately 78.5% gross margin |
| Research and development expense | $571.0 million | $397.5 million | Up 43.6%, including $86.7 million of non-cash acquisition-related IPR&D expense |
| Selling, general and administrative expense | $344.5 million | $265.8 million | Up 29.6%, including expanded commercial and brensocatib launch-readiness spending |
| Operating loss | $709.6 million | $457.3 million | Loss widened |
| Net loss | $749.6 million | $481.5 million | Loss widened; basic and diluted loss per share was $5.34 versus $3.91 |
| Cash used in operating activities | $536.2 million | $400.4 million | Cash burn increased |
| Cash and cash equivalents | $482.4 million | $1,074.0 million | Year-end balance |
| Marketable securities | $298.1 million | $74.2 million | Year-end balance; cash plus securities totaled $780.4 million |
| Working capital | $703.4 million | $1,083.1 million | Decreased year over year |
Investment income rose to $42.1 million from $11.1 million, while interest expense increased to $81.7 million from $26.4 million, primarily reflecting the term loan and royalty financing entered into in 2022. The company reported an accumulated deficit of $3.4 billion and stated it expects continued operating losses.
Debt, financing and commitments
- Long-term debt carrying value was $1.155 billion at year-end, comprising convertible notes and the Pharmakon term loan. Outstanding principal included $225 million of 2025 convertible notes and $575 million of 2028 convertible notes.
- The $350 million senior secured term loan matures in 2027 and bears interest at SOFR, subject to a 2.5% floor, plus 7.75%. The filing reports $27.5 million of capitalized paid-in-kind interest by year-end 2023. Repayment is scheduled to begin in 2026, with a conditional option to defer commencement.
- The OrbiMed royalty financing had a $155.0 million carrying value. It entitles OrbiMed to 4% of ARIKAYCE global net sales before September 1, 2025, 4.5% thereafter, and 0.75% of brensocatib global net sales if approved; payments are capped at 1.8x, or under specified conditions 1.9x, the $150 million purchase price.
- Insmed raised $152.2 million net through its ATM equity program in 2023, issuing about 6.5 million shares; $58.7 million remained available under the program at year-end.
- Management said available cash and marketable securities were expected to fund operations for at least 12 months. It also said additional capital may be needed; funding needs depend on clinical outcomes, commercial spending and development plans.
- Disclosed commitments include approximately $430.1 million of expected costs under PPD clinical-services project addenda, $92.7 million of firm purchase commitments, and an estimated $104 million investment to expand ARIKAYCE production capacity with Patheon and related suppliers.
Material changes and unusual items
- Revenue growth was outweighed by higher operating expenses, and net loss increased by $268.0 million. R&D growth included $86.7 million of one-time, non-cash asset-acquisition costs for Vertuis and Adrestia; SG&A growth reflected headcount, external costs and brensocatib preparation.
- Change in fair value of deferred and contingent consideration was a $28.7 million expense in 2023, versus a $20.8 million gain in 2022, primarily reflecting changes in share price and milestone assumptions.
- ARIKAYCE revenue by geography: US $224.2 million, Japan $65.7 million, and Europe/rest of world $15.3 million. The 2022 comparison included a $7.5 million French reimbursement-price revenue reduction, of which $5.8 million related to periods before 2022.
- Insmed acquired Vertuis in January and Adrestia in June 2023. The Adrestia transaction included 3.43 million shares issued at closing and contingent cash payments of up to $326.5 million, plus potential royalties. Acquisition-related milestone liabilities are estimates and can change.
- The top three customers generated 88% of gross product revenue in 2023, compared with 90% in 2022, creating material customer concentration.
Outlook, milestones and principal risks
- ARIKAYCE: FDA approval in the US remains accelerated and contingent on confirmatory post-marketing work. ARISE met its primary objective of validating the QOL-B respiratory domain as a patient-reported outcome tool. Insmed proposed it as ENCORE’s primary endpoint and was awaiting FDA guidance; ENCORE enrollment continued after reaching the original target of 250 patients. Topline ENCORE data were anticipated in 2025. Failure or delay could jeopardize full US approval.
- Brensocatib: Enrollment in the Phase 3 ASPEN bronchiectasis study was completed with 1,682 adults; topline results were anticipated in the latter half of the second quarter of 2024. The company initiated a Phase 2b study in chronic rhinosinusitis without nasal polyps and expected to start a hidradenitis suppurativa Phase 2 study in the second half of 2024. If approved, Insmed anticipated a US launch in mid-2025, followed by Europe and Japan in the first half of 2026.
- TPIP: The Phase 2 PH-ILD study completed enrollment of 39 patients, with topline results anticipated in the second quarter of 2024. The PAH study was ongoing, with 45 of an anticipated 99 patients enrolled at year-end and topline results expected in 2025. Management cautioned that interim, blended and blinded observations may differ materially from final results.
- Management expected R&D and SG&A expenses to rise in 2024, driven by trials and commercial readiness. There is no specific revenue, earnings or cash-flow guidance in the provided filing text.
- Key risks include reliance on ARIKAYCE as the sole approved product; confirmatory-trial and regulatory uncertainty; clinical and safety risks for pipeline candidates; reimbursement and drug-pricing pressure; reliance on a limited number of manufacturers and PARI as the sole Lamira supplier; customer concentration; ongoing cash burn and substantial debt; potential dilution; and execution risks from acquisitions and growth.
- Management said ordinary-course legal matters were not expected to materially affect financial position, results or cash flows. No material cybersecurity incident was known for 2023. Disclosure controls and internal controls were reported effective.
Important facts for investors to verify
- Review FDA feedback and final endpoint, statistical plan and enrollment target for ENCORE, and track progress toward the required full approval of ARIKAYCE.
- Check final ASPEN and TPIP trial results against the stated timelines and assess safety, efficacy and regulatory implications.
- Monitor quarterly ARIKAYCE sales, net pricing, geographic growth, rebates and customer concentration, particularly the reliance on three customers.
- Assess cash burn against the $780.4 million of year-end cash and marketable securities, including the expected 2024 expense increases and stated 12-month funding outlook.
- Track debt service and covenants, the 2025 convertible-note maturity, royalty-financing payments, and the potential effects of further equity issuance.
- Verify progress, timing and cost of Patheon capacity expansion and the company’s continued dependence on third-party manufacturing and Lamira supply.